Abstract 15751: Pharmacodynamic Effect of ARO-ANG3, an Investigational RNA Interference Targeting Hepatic Angiopoietin-like Protein 3, in Patients With Hypercholesterolemia

医学 PCSK9 安慰剂 药效学 内科学 甘油三酯 家族性高胆固醇血症 他汀类 内分泌学 脂蛋白 胃肠病学 胆固醇 药理学 药代动力学 低密度脂蛋白受体 病理 替代医学
作者
Gerald F. Watts,Christian Schwabe,Russell Scott,Patrick Gladding,David Sullivan,John E. Baker,Peter Clifton,James Hamilton,Bruce D. Given,Javier San Martín,Stacey Melquist,Ting Chang,Natasa Rajicic,Ira J. Goldberg,Daniel Gaudet,Joshua W. Knowles,Robert A. Hegele,Christie M. Ballantyne
出处
期刊:Circulation [Lippincott Williams & Wilkins]
卷期号:142 (Suppl_3) 被引量:33
标识
DOI:10.1161/circ.142.suppl_3.15751
摘要

Background: Angiopoietin-like protein 3 (ANGPTL3) regulates triglyceride (TG) and lipoprotein (LP) metabolism by inhibiting liver and endothelial LP lipases and reduces plasma LDL-C. In Phase 1 Study AROANG1001 (NCT03747224), single and multiple doses of RNA interference therapeutic ARO-ANG3 (100, 200, or 300 mg; n=36) in healthy volunteers substantially reduced ANGPTL3, LDL-C, and other LPs (AHA 2019) compared with placebo (n=16). Purpose: We report preliminary results following repeat doses (days 1 and 29) of ARO-ANG3 in patients with heterozygous familial hypercholesterolemia (FH) with elevated LDL-C despite statin therapy and average LDL-C of 130 mg/dL. An additional group (non-FH patients) had LDL-C > 70 mg/dL despite statin therapy. Methods: Seventeen FH patients received open-label, subcutaneous, ARO-ANG3 100 mg (n=6), 200 mg (n=6), or 300 mg (n=5). Nine non-FH, high risk patients with elevated LDL-C not at goal received either 200 mg ARO-ANG3 (n=6) or placebo (n=3) using a randomized double-blind design. Pharmacodynamic markers included serum ANGPTL3, LDL-C, TG, and others. Results: Results are reported as of 04 May 2020. In FH patients, ARO-ANG3 significantly reduced mean ANGPTL3 levels between 62-92% at week 16 in a dose-dependent manner (Table). LDL-C (23-37%) and TG (25-43%) were consistently reduced at all doses (Table). The mean percent reductions in non-FH patients for ANGPTL3 (85%), LDL-C (28%), and TG (29%) were comparable to those in FH patients, despite their initially lower LDL-C at baseline. As of 15 May 2020, there were no drug-related serious or severe adverse events (AEs) or discontinuations and most AEs were mild. The most common AEs reported in subjects receiving ARO-ANG3 were respiratory tract infection (30% of subjects) and injection site AEs (13% of subjects). Conclusions: In FH and non-FH patients, repeat doses of ARO-ANG3 significantly reduced ANGPTL3, LDL-C, and TG, with favorable safety.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Estrella的应助被Wenlia采纳,获得10
刚刚
可爱的函函的应助被小甲鱼采纳,获得10
刚刚
大个的应助被以七采纳,获得10
刚刚
Lud030发布了新的文献求助10
1秒前
inn发布了新的文献求助30
1秒前
初初初啊发布了新的文献求助10
2秒前
2秒前
野猪完成签到,获得积分10
2秒前
尊敬元芹完成签到,获得积分10
3秒前
柒柒完成签到,获得积分10
3秒前
3秒前
Tina发布了新的文献求助10
4秒前
朴素旭尧完成签到,获得积分10
5秒前
5秒前
今后的应助被WangChangman采纳,获得10
6秒前
6秒前
7秒前
8秒前
王圣文发布了新的文献求助10
8秒前
8秒前
10秒前
秋qiu完成签到,获得积分10
10秒前
大个的应助被局外人采纳,获得10
11秒前
282828发布了新的文献求助10
11秒前
11秒前
乌龙茶发布了新的文献求助10
11秒前
为难完成签到,获得积分20
11秒前
Auster发布了新的文献求助10
11秒前
12秒前
科研通AI2S的应助被坦率采纳,获得10
12秒前
12秒前
教笑阳完成签到,获得积分10
12秒前
13秒前
13秒前
盖饭不加辣完成签到,获得积分10
14秒前
15秒前
15秒前
16秒前
starstar发布了新的文献求助10
16秒前
村村发布了新的文献求助10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165074
求助须知:如何正确求助?哪些是违规求助? 9558738
关于积分的说明 21747291
捐赠科研通 7755624
什么是DOI,文献DOI怎么找? 3428780
关于科研通互助平台的介绍 2553162
邀请新用户注册赠送积分活动 2473361